Literature DB >> 28667756

Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.

Mitsutaka Osawa1, Norio Akuta1, Fumitaka Suzuki1, Shunichiro Fujiyama1, Yusuke Kawamura1, Hitomi Sezaki1, Tetsuya Hosaka1, Masahiro Kobayashi1, Mariko Kobayashi1, Satoshi Saitoh1, Yasuji Arase1, Yoshiyuki Suzuki1, Kenji Ikeda1, Hiromitsu Kumada1.   

Abstract

With rapidly aging population in the world, many elderly patients present with hepatitis B virus (HBV) infection. We conducted a retrospective cohort study involving 359 untreated HBV patients aged 60 and older who were free of hepatocellular carcinoma (HCC) and acute hepatitis at the initial visit, and examined the incidence of HCC and liver-related mortality rate. During the follow-up period of 7.9 years (range, 0-25 years), 26 patients (7.2% of patients) developed HCC, 20 patients died from liver-related diseases (61% of total deaths), including HCC, liver failure, and gastrointestinal bleeding. The cumulative rates of HCC at years 5, 10, and 15 were 6.5%, 15.6%, and 15.6%, respectively. The cumulative rates of mortality from liver-related diseases at years 5, 10, 15 were 3.3%, 12.3%, and 15.7%, respectively. Multivariate analysis identified HBV DNA (≥5.0 Log IU/mL), male gender, and FIB4-Index (≥3.6) as significant independent risk factors for HCC, and alpha-fetoprotein (≥10 ng/mL) as significant independent predictors of liver-related mortality. We conclude that high levels of HBV DNA, progression of liver fibrosis, and male gender are independent risk factors of HCC in untreated patients infected with HBV aged 60 and older.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  FIB4-index; HBV; HBV DNA; elderly; hepatocellular carcinoma; mortality

Mesh:

Substances:

Year:  2017        PMID: 28667756     DOI: 10.1002/jmv.24890

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B.

Authors:  De Zhao Kong; Ning Liang; Guan Lin Yang; Zhe Zhang; Yue Liu; Jing Li; Xuehan Liu; Shibing Liang; Dimitrinka Nikolova; Janus C Jakobsen; Christian Gluud; Jian Ping Liu
Journal:  Cochrane Database Syst Rev       Date:  2019-11-07

Review 2.  Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma.

Authors:  Nighat Gull; Fareeha Arshad; Gowhar A Naikoo; Israr Ul Hassan; Mona Zamani Pedram; Arif Ahmad; Alaa A A Aljabali; Vijay Mishra; Saurabh Satija; Nitin Charbe; Poonam Negi; Rohit Goyal; Ángel Serrano-Aroca; Mazhar S Al Zoubi; Mohamed El-Tanani; Murtaza M Tambuwala
Journal:  J Gastrointest Cancer       Date:  2022-03-14

Review 3.  Viral Biomarkers in Chronic HBeAg Negative HBV Infection.

Authors:  Emilia Hadziyannis; Andreas Laras
Journal:  Genes (Basel)       Date:  2018-09-27       Impact factor: 4.096

Review 4.  Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges.

Authors:  Shen Li; Antonio Saviano; Derek J Erstad; Yujin Hoshida; Bryan C Fuchs; Thomas Baumert; Kenneth K Tanabe
Journal:  J Clin Med       Date:  2020-11-25       Impact factor: 4.241

5.  Nomogram for Predicting the Prognoses of Patients With Pancreatic Head Cancer After Pancreaticoduodenectomy: A Population-Based Study on SEER Data.

Authors:  Wei Zhang; Lin Xu; Xu Che
Journal:  Front Oncol       Date:  2021-11-04       Impact factor: 6.244

6.  Prognostic Analysis of Postoperative Survival for Ruptured Hepatocellular Carcinoma with or without Cirrhosis.

Authors:  Feng Xia; Peng Zhu; Xiao-Ping Chen; Bi-Xiang Zhang; Ming-Yu Zhang
Journal:  J Oncol       Date:  2022-03-17       Impact factor: 4.375

7.  Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.

Authors:  Sung Won Lee; Jung Hyun Kwon; Hae Lim Lee; Sun Hong Yoo; Hee Chul Nam; Pil Soo Sung; Soon Woo Nam; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Nam Ik Han; Jeong Won Jang
Journal:  Gut       Date:  2019-10-31       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.